Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome

Key facts

Sponsor

Lexicon Pharmaceuticals

Principal Investigator

Pablo LaPuerta, MD

Lexicon Pharmaceuticals, Inc.

Intervention

Telotristat etiprate(drug)

Enrollment

15 enrolled

Eligibility

18 years · All sexes

Timeline

2010 – 2014

Study locations (10)

• Lexicon Investigational Site, Bad Berka, Germany
• Lexicon Investigational Site, Berlin, Germany
• Lexicon Investigational Site, Halle, Germany
• Lexicon Investigational Site, Lübeck, Germany
• Lexicon Investigational Site, Marburg, Germany
• Lexicon Investigational Site, Munich, Germany
• Lexicon Investigational Site, Basingstoke, United Kingdom
• Lexicon Investigational Site, Cambridge, United Kingdom
• Lexicon Investigational Site, London, United Kingdom
• Lexicon Investigational Site, Manchester, United Kingdom

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Carcinoid syndrome

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE3NCT07087054
  Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
  Crinetics Pharmaceuticals Inc.
• RECRUITINGNCT05756608
  Fibrosis in Chronic and Delayed Myocardial Infarction
  University of Edinburgh
• ACTIVE NOT RECRUITINGNANCT05064514
  Investigation of a Transcatheter Tricuspid Valved Stent Graft in Patients With Carcinoid Heart Disease
  Queen Mary University of London
• ACTIVE NOT RECRUITINGEARLY PHASE1NCT04993261
  An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors
  M.D. Anderson Cancer Center

See all trials for Carcinoid syndrome →